{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347984","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2026-08-13T12:31:59+00:00","discovered_at":"2026-08-13T12:35:00.374875+00:00","generated_at":"2026-08-13T12:35:09.638038+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fate Therapeutics Q2 net loss narrows to $30.2M; first patient dosed in lupus nephritis registrational trial","bullets":["Net loss $30.2M ($0.25/share) vs $34.1M ($0.29/share) in Q2 2025; revenue $2.1M from Ono collaboration.","Cash $153.8M at June 30, down $21M in quarter; runway expected into 2028.","First patient dosed in RECLAIM-LN Phase 2 registrational trial for lupus nephritis with FT819; outpatient same-day discharge.","FDA cleared IND for FT839 dual CD19/CD38 CAR T; Phase 1/2 basket trial in autoimmune disease planned.","Preliminary SSc data: all 4 patients achieved rCRISS≥25 and mRSS improvement; no CRS/ICANS/GvHD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347984","json":"https://secwatch.observer/filing/0001193125-26-347984.json","markdown":"https://secwatch.observer/filing/0001193125-26-347984.md","text":"https://secwatch.observer/filing/0001193125-26-347984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/0001193125-26-347984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:35:09.638038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}